CPT code 0717T documents harvest and processing of a patient’s adipose-derived cells to create a concentrated regenerative cell product for a separately reportable injection to treat a partial-thickness rotator cuff tear. The code captures the biologic preparation step distinct from the injection procedure itself and is relevant as interest in orthobiologic therapies grows nationwide. Payers and providers evaluate this code for medical necessity, bundling, and coverage under emerging regenerative medicine policies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national overview of clinical context for autologous adipose-derived cell therapies for rotator cuff pathology, common billing considerations, and how major payers approach coverage and coding for biologic preparation services. The publication highlights typical sites of service—ambulatory surgery centers, hospital outpatient departments, and outpatient procedure suites—and clarifies that the injection is reported separately.

This resource is intended to inform coding professionals, revenue cycle staff, and clinical leaders about the role of CPT code 0717T in billing workflows, the clinical scenario it represents, and the types of benchmarks and policy updates to monitor as regenerative musculoskeletal treatments evolve. Data not available in the input will be noted where relevant in subsequent sections.